P10.03 Pembrolizumab With or Without Chemotherapy for Advanced Lung Cancer: A Real-World Analysis of Key Prognostic Factors
Shirish M. Gadgeel(Chinese University of Hong Kong), T.D. Brown(Duke University), Connor Sweetnam, Jonathan Treisman(Ascension), Monika A. Izano(Syndicat des Sélectionneurs Avicoles et Aquacoles Français), Aalok Patel(Ascension), James L. Weese(Penn Presbyterian Medical Center), Frank Wolf, Andrew Stafford, Mohamed Hendawi(Aurora Health Care), Douglas J. Reding(Ascension), C. Zhang, Igor I. Rybkin(Henry Ford Hospital)
Cited by 0
Related Papers
Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial
|The Lancet|2016|4.8k
Mortality Results from a Randomized Prostate-Cancer Screening Trial
|New England Journal of Medicine|2009|2.9k
Alectinib versus Crizotinib in Untreated <i>ALK</i>-Positive Non–Small-Cell Lung Cancer
|New England Journal of Medicine|2017|2.4k
Prostate Cancer Screening in the Randomized Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial: Mortality Results after 13 Years of Follow-up
|JNCI Journal of the National Cancer Institute|2012|1.1k
Design of the prostate, lung, colorectal and ovarian (PLCO) cancer screening trial
|Controlled Clinical Trials|2000|1k